Class Action Lawsuit Against Applied Therapeutics: What Investors Need to Know

NEW YORK, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a well-known law firm, is alerting investors that a class action lawsuit has been initiated against Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") under the ticker APLT and some of its officers.

Understanding the Class Definition

This class action aims to recover financial damages from the defendants for alleged breaches of federal securities laws. It covers all individuals or entities that purchased or acquired securities of Applied Therapeutics from January 3, 2024, to December 2, 2024, inclusive (the "Class Period"). Investors who believe they qualify are encouraged to join the case by visiting the law firm's website.

Details of the Case

The lawsuit claims that throughout the Class Period, the defendants made false and misleading statements or failed to disclose critical information, including: (1) the New Drug Application (NDA) for govorestat had issues that would hinder FDA approval; (2) the clinical data provided for the NDA did not adequately demonstrate safety or effectiveness; (3) earlier positive statements regarding the likelihood of obtaining approval for govorestat were materially misleading; and (4) as a result, the public statements made by Applied Therapeutics lacked a reasonable foundation and were materially false.

Next Steps for Investors

A class action complaint has been filed. Anyone interested in reviewing the Complaint can visit the designated site of the law firm. Investors may also contact Peretz Bronstein, Esq. or Client Relations Manager Nathan Miller at Bronstein, Gewirtz & Grossman, LLC. If you experienced a loss from your investment in Applied Therapeutics, you have until February 18, 2025, to request that the court appoint you as the lead plaintiff. However, participation in any recovery does not necessitate being the lead plaintiff.

Cost Structure for Investors

The firm operates on a contingency fee basis, meaning they will only seek reimbursement for out-of-pocket costs and attorney fees from the court if they win the case. This structure alleviates any financial burden for clients unless a successful recovery is made.

About Bronstein, Gewirtz & Grossman, LLC

This law firm is nationally recognized for representing investors in class actions related to securities fraud and shareholder derivative suits. The firm has successfully recovered hundreds of millions of dollars for investors across the country.

Stay Informed

For future updates, consider following Bronstein, Gewirtz & Grossman, LLC on their social media platforms.

Attorney advertising. Past outcomes do not guarantee future results.

Contact Information

If you have questions or need more information, reach out to:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660
[email protected]

lawsuit, investors, AppliedTherapeutics